Juan Monteverde founder and managing partner at Monteverde & Associates PC a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City is investigating Trillium Therapeutics, Inc. relating to its proposed acquisition by Landmark Dividend LLC. Under the terms of the agreement, TRIL shareholders will receive ...

Juan Monteverde founder and managing partner at Monteverde & Associates PC a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City is investigating Trillium Therapeutics, Inc. ("TRIL" or the "Company") ( TRIL ) relating to its proposed acquisition by Landmark Dividend LLC. Under the terms of the agreement, TRIL shareholders will receive $16.50 in cash per share they own.

The investigation focuses on whether Trillium Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Click here for more information: http://monteverdelaw.com/case/trillium-therapeutics-inc . It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. We were listed in the Top 50 in the 2018-2020 ISS Securities Class Action Services Report. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale -Hubbell as a 2017-2020 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian , 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.

If you owned common stock in the Company and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2021 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( www.monteverdelaw.com ). Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-trillium-therapeutics-inc--tril-301373697.html

SOURCE Monteverde & Associates PC

News Provided by PR Newswire via QuoteMedia

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

- ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019 . This action is pending in the United States District Court for the Southern District of New York .

Get Help
BMS investors should visit us at https://claimsfiler.com/cases/nyse-bmy-3/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

Keep reading... Show less
New Research Analysis Shows VINIA Reduces Oxidation Of LDL-Cholesterol To Support Cardiovascular Improved Functioning

New Research Analysis Shows VINIA Reduces Oxidation Of LDL-Cholesterol To Support Cardiovascular Improved Functioning

New research analysis affirms the addition of the following structure function claims for VINIA® according to FDA Guidelines for Dietary Supplements:

  • VINIA® prevents Lipid Oxidation
  • VINIA® protects the body by preventing oxidative damage to the cells
  • VINIA® reduces oxidation of LDL cholesterol

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") reports that recent research analysis provides additional support for anti-oxidation structurefunction claims of VINIA®. This analysis, when added to the clinical study [1] conducted by the Company, provides a clear substantiation to BioHarvest's claims relating to anti-oxidation, lipid anti-oxidation, and scavenging free radicals.

Keep reading... Show less

Amgen Announces Positive Top-Line Results From Otezla® Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response (defined as an sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16.

In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of ≥ 4); affected body surface area (BSA) change from baseline; Dermatology Life Quality Index (DLQI) change from baseline; and static Physician's Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo.

Keep reading... Show less

FDA Approves New KYPROLIS® Combination Regimen With DARZALEX FASPRO® and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

"I am pleased that the addition of subcutaneous daratumumab to KYPROLIS plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden," said David M. Reese , M.D., executive vice president of Research and Development at Amgen.

Keep reading... Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - December 1st 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS)

Keep reading... Show less

Top News

Related News